I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 18% revenue growth, improved gross margins, and a return to profitability, driven by strong domestic and international core performance. Guidance for 2026 was raised, with revenue expected to grow 15–18% and gross margin to reach 62–64%.Original document: KORU Medical Systems, Inc. [KRMD] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 18% revenue growth, improved gross margins, and a return to profitability, driven by strong domestic and international core performance. Guidance for 2026 was raised, with revenue expected to grow 15–18% and gross margin to reach 62–64%.
Original document: KORU Medical Systems, Inc. [KRMD] SEC 8-K Current Report — Aug. 5 2026